STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIP
  4. [Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity

ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an open-market sale of 2,850 shares of common stock at a weighted average price of $84.12 per share. After the sale, he directly holds 177,543 shares, indicating that the transaction represents a small portion of his overall stake.

The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and occurred in multiple transactions at prices ranging from $83.39 to $84.63. Such plans are designed to allow insiders to sell shares over time according to preset instructions.

Positive

  • None.

Negative

  • None.
Insider CAREY STEPHEN P.
Role SVP & CFO
Sold 2,850 shs ($240K)
Type Security Shares Price Value
Sale Common Stock 2,850 $84.12 $240K
Holdings After Transaction: Common Stock — 177,543 shares (Direct)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026. The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price.
Shares sold 2,850 shares Open-market sale of common stock
Weighted average sale price $84.12 per share Average price across multiple trades
Post-transaction holdings 177,543 shares Shares directly owned after sale
Trade price range $83.39–$84.63 per share Range of prices for individual trades
Trading plan adoption date March 6, 2026 Rule 10b5-1 plan for reported sales
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average sales price financial
"The price reported above reflects the weighted average sales price."
Form 4 regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Stephen P. Carey?
ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock in an open-market transaction at a weighted average price of $84.12 per share. This filing documents the sale and the executive’s updated share ownership position.

How many ANI Pharmaceuticals (ANIP) shares does Stephen P. Carey hold after this sale?
Following the reported sale, Stephen P. Carey directly holds 177,543 shares of ANI Pharmaceuticals common stock. This shows that the 2,850 shares sold represent only a small fraction of his overall equity position in the company after the transaction.

At what prices were Stephen P. Carey’s ANI Pharmaceuticals (ANIP) shares sold?
The shares were sold in multiple trades at prices ranging from $83.39 to $84.63 per share. The Form 4 reports a weighted average sale price of $84.12 per share, reflecting the combined pricing across all individual trades executed that day.

Was Stephen P. Carey’s ANI Pharmaceuticals (ANIP) stock sale under a Rule 10b5-1 plan?
Yes. The filing states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Stephen P. Carey on March 6, 2026. Such plans pre-schedule trades, helping separate routine portfolio management from market-timed insider decisions.

What type of transaction is reported in Stephen P. Carey’s ANI Pharmaceuticals (ANIP) Form 4?
The Form 4 reports an open-market sale of common stock, coded as transaction type “S.” This indicates a standard sale in the market or a private transaction, not an option exercise, grant, gift, or tax-withholding-related disposition of ANI Pharmaceuticals shares.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAREY STEPHEN P.
(Last)(First)(Middle)
C/O ANI PHARMACEUTICALS, INC.
104 CARNEGIE CENTER, SUITE 300
(Street)
PRINCETON NEW JERSEY 08540
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP & CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/29/2026S(1)2,850D$84.12(2)177,543D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price.
Remarks:
/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR